Griessenauer Christoph J, Ghozy Sherief, Biondi Alessandra, Hecker Constantin, Wodarg Fritz, Liebig Thomas, Patankar Tufail, Lamin Saleh, Martínez-Galdámez Mario, Cognard Christophe, Fiehler Jens, Dorn Franziska, Dmytriw Adam A, Killer-Oberpfalzer Monika
Department of Neurosurgery, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
J Neurointerv Surg. 2025 Mar 17;17(4):399-404. doi: 10.1136/jnis-2023-021378.
Intrasaccular devices have become increasingly popular in the treatment of cerebral aneurysms, particularly at the bifurcation. Here we evaluate the Contour Neurovascular System, an intrasaccular device for the endovascular treatment of cerebral aneurysms, in a multicenter cohort study, the largest to the best of our knowledge.
Consecutive patients with intracranial aneurysms treated with the Contour Neurovascular System between February 2017 and October 2022 at 10 European neurovascular centers were prospectively collected and retrospectively reviewed. Patient and aneurysm characteristics, procedural details, and angiographic and clinical outcomes were evaluated.
During the study period, 279 aneurysms (median age of patients 60 years, IQR 52-68) were treated with Contour. In 83.2% of patients the device was placed electively, whereas the remaining patients were treated in the setting of acute subarachnoid hemorrhage. The most common locations were the middle cerebral artery (26.5%) followed by the anterior communicating region (26.2%). Median aneurysm dome and neck size were 5.2 mm (IQR 4.2-7) and 3.9 mm (IQR 3-5). Contour size 7 (39%) and 9 (25%) were most used. Thromboembolic and hemorrhagic complications occurred in 6.8% and 0.4% of aneurysms, respectively. Raymond-Roy 1 and 2 occlusions at last follow-up were achieved in 63.2% and 28.3%, respectively, resulting in adequate occlusion of 91.5% of aneurysms.
This is the largest multicenter study reporting the outcome on the Contour Neurovascular System. At 1 year, the self-evaluated data on safety and efficacy are comparable to data of existing intrasaccular devices. Contour is a promising technology in the treatment of cerebral aneurysms.
囊内装置在脑动脉瘤治疗中越来越受欢迎，尤其是在分叉处。在此，我们在一项多中心队列研究中评估了用于脑动脉瘤血管内治疗的囊内装置Contour神经血管系统，据我们所知，这是最大规模的此类研究。
前瞻性收集并回顾性分析了2017年2月至2022年10月期间在10个欧洲神经血管中心接受Contour神经血管系统治疗的颅内动脉瘤连续患者。评估了患者和动脉瘤的特征、手术细节以及血管造影和临床结果。
在研究期间，使用Contour治疗了279个动脉瘤（患者中位年龄60岁，四分位间距52 - 68岁）。83.2%的患者为择期置入该装置，其余患者在急性蛛网膜下腔出血情况下接受治疗。最常见的部位是大脑中动脉（26.5%），其次是前交通区域（26.2%）。动脉瘤穹顶和颈部大小的中位数分别为5.2毫米（四分位间距4.2 - 7）和3.9毫米（四分位间距3 - 5）。最常用的Contour尺寸为7（39%）和9（25%）。血栓栓塞和出血并发症分别发生在6.8%和0.4%的动脉瘤中。末次随访时分别有63.2%和28.3%的动脉瘤实现了Raymond - Roy 1级和2级闭塞，从而使91.5%的动脉瘤实现了充分闭塞。
这是报告Contour神经血管系统结果的最大规模多中心研究。在1年时，自我评估的安全性和有效性数据与现有囊内装置的数据相当。Contour是一种有前景的脑动脉瘤治疗技术。
